XOMA Corporation (NASDAQ:XOMA) Rating Changes as of May 17, 2018

May 17, 2018 - By Nellie Rakes

XOMA Corporation (NASDAQ:XOMA) Corporate Logo

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

Total analysts of 2 have positions in Xoma Corp (NASDAQ:XOMA) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 7, 2017 according to StockzIntelligence Inc Xoma Corp has 6 analyst reports. In Tuesday, February 6 report Wedbush maintained the stock with “Buy” rating. The stock rating was maintained by H.C. Wainwright with “Buy” on Friday, March 9. On Thursday, December 7 H.C. Wainwright maintained XOMA Corporation (NASDAQ:XOMA) rating. H.C. Wainwright has “Buy” rating and $38.0 target. In Monday, April 30 report H.C. Wainwright maintained the stock with “Buy” rating. On Thursday, January 18 the firm has “Buy” rating by H.C. Wainwright given. On Tuesday, December 19 Wedbush maintained the shares of XOMA in report with “Buy” rating. Listed here are XOMA Corporation (NASDAQ:XOMA) PTs and latest ratings.

30/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0000 Maintain
09/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain
06/02/2018 Broker: Wedbush Rating: Buy New Target: $33.0 Maintain
18/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain
19/12/2017 Broker: Wedbush Rating: Buy New Target: $33.0 Maintain
07/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $38.0 Maintain

The stock decreased 2.69% or $0.68 during the last trading session, hitting $24.6.XOMA Corporation has volume of 72,030 shares. Since May 17, 2017 XOMA has risen 184.45% and is uptrending. XOMA outperformed the S&P500 by 172.90%.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific.The firm is worth $205.83 million. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia.11.2 is the P/E ratio. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

Another two news for XOMA Corporation (NASDAQ:XOMA) were recently published by: Nasdaq.com on May 09, 2018 with title “XOMA Reports First Quarter 2018 Financial Results”. The other Globenewswire.com‘s article was titled “New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares …” and published on May 02, 2018.

XOMA Corporation (NASDAQ:XOMA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.